AEGLEA BIOTHERAPEUTICS

Summary

Aeglea is a biotechnology company focused on advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 87 M

Avg. Deal Size£ 87 M

Market Context

Senior Management

Jonathan Alspaugh
President and CFO